MedTrace Logo

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

NCT07250737 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-12

No results posted yet for this study

Summary

The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Conditions

  • Muscular Disorders, Atrophic
  • Muscular Diseases
  • Musculoskeletal Diseases
  • Neuromuscular Diseases
  • Nervous System Diseases
  • Genetic Diseases, Inborn
  • Genetic Diseases, X-Linked
  • Muscular Dystrophies
  • Muscular Dystrophy, Duchenne

Interventions

DRUG

delpacibart zotadirsen

Del-zota is administered as an IV infusion every 6 weeks. Doses are administered based on body weight.

Sponsors & Collaborators

  • Clinigen Healthcare Limited

    collaborator UNKNOWN

  • Avidity Biosciences, Inc.

    lead INDUSTRY

Eligibility

Min Age
6 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07250737 on ClinicalTrials.gov